表紙
市場調查報告書

基質細胞衍生因子1:開發中產品分析

Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 364868
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
基質細胞衍生因子1:開發中產品分析 Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 66 Pages
簡介

本報告提供以基質細胞衍生因子1為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

基質細胞衍生因子1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Juventas Therapeutics, Inc.
  • Momenta Pharmaceuticals, Inc.
  • Noxxon Pharma AG
  • TikoMed AB

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1987TDB

Summary

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Stromal Cell Derived Factor 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Stromal cell-derived factor 1 (SDF1) or C-X-C motif chemokine 12 (CXCL12) is a chemokine protein encoded by the CXCL12 gene. It activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. It binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. It acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. It stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1.

The molecules developed by companies in Phase II and Preclinical stages are 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genetic Disorders and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Pancreatic Ductal Adenocarcinoma, B-Cell Chronic Lymphocytic Leukemia, Chronic Heart Failure, Critical Limb Ischemia, Fecal Incontinence, Glioblastoma Multiforme (GBM), Lung Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Ovarian Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Traumatic Brain Injury, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

Furthermore, this report also reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)
  • The report reviews Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Overview
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Companies Involved in Therapeutics Development
  • Biokine Therapeutics Ltd
  • Chimerix Inc
  • Juventas Therapeutics Inc
  • Noxxon Pharma AG
  • OncoTrap Inc
  • TikoMed AB
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Drug Profiles
  • BKT-300 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dociparstat sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IBsolvMIR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JVS-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • olaptesed pegol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OT-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CXCL12 for WHIM Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CXCL12 for Metastatic Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Dormant Products
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Discontinued Products
  • Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting
  • Oct 17, 2019: Noxxon Pharma studies combination therapy for brain cancer
  • Sep 29, 2019: NOXXON presents latest clinical data from phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO Congress
  • Sep 18, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO Congress
  • Sep 12, 2019: NOXXON initiates patient recruitment for phase 1/2 Clinical Trial combining NOX-A12 & Radiotherapy for the treatment of Brain Cancer Patients
  • Jun 24, 2019: NOXXON announces leading international pharma to evaluate NOX-A12 in new indication
  • Apr 01, 2019: Noxxon presents updated results from phase 1/2 NOX-A12 /Keytruda combination trial at AACR 2019
  • Mar 04, 2019: TFS International appointed CRO representative for TIKOMED's phase 2 study in clinical islet transplantation
  • Feb 28, 2019: NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting
  • Feb 27, 2019: Noxxon Files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of Brain Cancer Patients
  • Dec 14, 2018: NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients
  • Dec 10, 2018: NOXXON to present latest clinical data from Nox-A12 / Keytruda combination trial at Esmo Immuno-Oncology Congress
  • Nov 30, 2018: TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
  • Nov 21, 2018: NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer
  • Nov 19, 2018: TIKOMED granted permission for phase 2 clinical trial in islet cell transplantation by the Swedish Medical Product Agency
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Biokine Therapeutics Ltd, H2 2019
  • Pipeline by Chimerix Inc, H2 2019
  • Pipeline by Juventas Therapeutics Inc, H2 2019
  • Pipeline by Noxxon Pharma AG, H2 2019
  • Pipeline by OncoTrap Inc, H2 2019
  • Pipeline by TikoMed AB, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019